MCID: 48X005
MIFTS: 39

48,xyyy

Categories: Fetal diseases, Neuronal diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for 48,xyyy

Summaries for 48,xyyy

NIH Rare Diseases : 52 The following summary is from Orphanet , a European reference portal for information on rare diseases and orphan drugs. Orpha Number: 99329 Definition A rare Y chromosome number anomaly that affects only males and is characterized by mild-moderate developmental delay (especially speech), normal to mild intellectual disability , large, irregular teeth with poor enamel, tall stature and acne. Radioulnar synostosis and clinodactyly have also been associated. Boys generally present normal genitalia, while hypogonadism and infertility is frequently reported in adult males. Visit the Orphanet disease page for more resources.

MalaCards based summary : 48,xyyy, also known as 48,xyyy syndrome, is related to radioulnar synostosis and hypogonadotropic hypogonadism. The drugs Progesterone and Ezetimibe have been mentioned in the context of this disorder. Affiliated tissues include testes, liver and lung, and related phenotypes are hypertelorism and short neck

Related Diseases for 48,xyyy

Diseases related to 48,xyyy via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 radioulnar synostosis 10.2
2 hypogonadotropic hypogonadism 10.2

Symptoms & Phenotypes for 48,xyyy

Human phenotypes related to 48,xyyy:

58 31 (show all 31)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 hypertelorism 58 31 hallmark (90%) Very frequent (99-80%) HP:0000316
2 short neck 58 31 hallmark (90%) Very frequent (99-80%) HP:0000470
3 high palate 58 31 hallmark (90%) Very frequent (99-80%) HP:0000218
4 global developmental delay 58 31 hallmark (90%) Very frequent (99-80%) HP:0001263
5 depressed nasal bridge 58 31 hallmark (90%) Very frequent (99-80%) HP:0005280
6 delayed speech and language development 58 31 hallmark (90%) Very frequent (99-80%) HP:0000750
7 pes planus 58 31 hallmark (90%) Very frequent (99-80%) HP:0001763
8 feeding difficulties 58 31 hallmark (90%) Very frequent (99-80%) HP:0011968
9 intellectual disability, mild 58 31 hallmark (90%) Very frequent (99-80%) HP:0001256
10 long philtrum 58 31 hallmark (90%) Very frequent (99-80%) HP:0000343
11 thick lower lip vermilion 58 31 hallmark (90%) Very frequent (99-80%) HP:0000179
12 recurrent upper respiratory tract infections 58 31 hallmark (90%) Very frequent (99-80%) HP:0002788
13 epicanthus 58 31 hallmark (90%) Very frequent (99-80%) HP:0000286
14 acne 58 31 hallmark (90%) Very frequent (99-80%) HP:0001061
15 abnormal dermatoglyphics 58 31 hallmark (90%) Very frequent (99-80%) HP:0007477
16 male hypogonadism 58 31 hallmark (90%) Very frequent (99-80%) HP:0000026
17 aggressive behavior 58 31 hallmark (90%) Very frequent (99-80%) HP:0000718
18 asthma 58 31 hallmark (90%) Very frequent (99-80%) HP:0002099
19 azoospermia 58 31 hallmark (90%) Very frequent (99-80%) HP:0000027
20 radioulnar synostosis 58 31 hallmark (90%) Very frequent (99-80%) HP:0002974
21 tall stature 58 31 hallmark (90%) Very frequent (99-80%) HP:0000098
22 impulsivity 58 31 hallmark (90%) Very frequent (99-80%) HP:0100710
23 abnormal renal morphology 58 31 hallmark (90%) Very frequent (99-80%) HP:0012210
24 primary gonadal insufficiency 58 31 hallmark (90%) Very frequent (99-80%) HP:0008193
25 dislocated radial head 58 31 hallmark (90%) Very frequent (99-80%) HP:0003083
26 hypoplasia of dental enamel 58 31 hallmark (90%) Very frequent (99-80%) HP:0006297
27 low frustration tolerance 58 31 hallmark (90%) Very frequent (99-80%) HP:0000744
28 irregularly spaced teeth 58 31 hallmark (90%) Very frequent (99-80%) HP:0006316
29 intellectual disability 58 Very frequent (99-80%)
30 behavioral abnormality 58 Very frequent (99-80%)
31 abnormality of the foot 58 Very frequent (99-80%)

Drugs & Therapeutics for 48,xyyy

Drugs for 48,xyyy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1658)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Progesterone Approved, Vet_approved Phase 4 57-83-0 5994
2
Ezetimibe Approved Phase 4 163222-33-1 150311
3
Amantadine Approved Phase 4 768-94-5 2130
4
Cefuroxime Approved Phase 4 55268-75-2 5479529 5361202
5
Digoxin Approved Phase 4 20830-75-5 30322 2724385
6
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
7
Nepafenac Approved, Investigational Phase 4 78281-72-8 151075
8
Fluvoxamine Approved, Investigational Phase 4 54739-18-3 3404 5324346
9
Riociguat Approved Phase 4 625115-55-1
10
Diltiazem Approved, Investigational Phase 4 42399-41-7 39186
11
Fenoldopam Approved Phase 4 67227-57-0, 67227-56-9 3341
12
Lincomycin Approved, Vet_approved Phase 4 154-21-2 656509
13
Hexetidine Approved, Investigational Phase 4 141-94-6
14
Eleuthero Approved, Experimental Phase 4
15
Bosentan Approved, Investigational Phase 4 147536-97-8 104865
16
Eszopiclone Approved, Investigational Phase 4 138729-47-2 969472
17
Trimetazidine Approved, Investigational Phase 4 5011-34-7
18
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
19
Donepezil Approved Phase 4 120014-06-4 3152
20
Nifedipine Approved Phase 4 21829-25-4 4485
21
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
22
Zidovudine Approved Phase 4 30516-87-1 35370
23
Saw palmetto Approved, Experimental, Investigational Phase 4
24
Flurbiprofen Approved, Investigational Phase 4 5104-49-4 3394
25
Neomycin Approved, Vet_approved Phase 4 1404-04-2 8378
26
Eplerenone Approved Phase 4 107724-20-9 150310 443872
27
Norepinephrine Approved Phase 4 51-41-2 439260
28
Terlipressin Approved, Investigational Phase 4 14636-12-5 72081
29
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
30
Pamidronate Approved Phase 4 40391-99-9 4674
31
Omalizumab Approved, Investigational Phase 4 242138-07-4
32
Dalteparin Approved Phase 4 9005-49-6
33
Saquinavir Approved, Investigational Phase 4 127779-20-8 60787
34
Interferon beta-1a Approved, Investigational Phase 4 145258-61-3 6438354
35
Natalizumab Approved, Investigational Phase 4 189261-10-7
36
Orphenadrine Approved Phase 4 83-98-7 4601
37
Neostigmine Approved, Vet_approved Phase 4 59-99-4 4456
38
Methocarbamol Approved, Vet_approved Phase 4 532-03-6 4107
39
Atorvastatin Approved Phase 4 134523-00-5 60823
40
Fosamprenavir Approved Phase 4 226700-79-4 131536
41
Etonogestrel Approved, Investigational Phase 4 54048-10-1 6917715 40976
42
Desogestrel Approved Phase 4 54024-22-5 40973
43
Tavaborole Approved, Investigational Phase 4 174671-46-6
44
Dezocine Approved, Investigational Phase 4 53648-55-8 40841 3033053
45
Nefopam Approved, Investigational Phase 4 13669-70-0
46
Salmon Calcitonin Approved, Investigational Phase 4 47931-85-1 16129616
47
chloroquine Approved, Investigational, Vet_approved Phase 4 54-05-7 2719
48
Etanercept Approved, Investigational Phase 4 185243-69-0
49
Prucalopride Approved Phase 4 179474-81-8
50
lanreotide Approved Phase 4 108736-35-2

Interventional clinical trials:

(show top 50) (show all 10000)
# Name Status NCT ID Phase Drugs
1 A Prospective, Randomized, Multicenter, Open-label Study Evaluating HBeAg Seroconversion in HBeAg Positive CHB Patients on Treatment With NA Switched to Combined Therapy With Peginterferon Alfa-2a and NA for 48 Weeks Unknown status NCT02474316 Phase 4 Peginterferon alfa-2a;nucleos(t)ide analgoue
2 Cost-effectiveness of Different Antiretroviral Treatment in Patients HIV Naive. Randomized Clinical, Not Masked, Trial Comparing DRVr3TC, ABC3TC (Kivexa) RPV, or EVG COBI FTC TDF (Stribild) for 48 Weeks Unknown status NCT02470650 Phase 4 elvitegravir/cobicistat/emtricitabine/tenofovir;Darunavir;abacavir/lamivudine;Ritonavir;Lamivudine;rilpivirine
3 Emtricitabine for Naive Chinese Pregnant Chronic Hepatitis B Patients Unknown status NCT02327702 Phase 4 Emtricitabine
4 Efficacy and Safety of Shenyankangfu Tablets for Primary Glomerulonephritis—a Multicentre, Prospective, Double-blind, Double-dummy, Randomized Controlled Clinical Trial Unknown status NCT02063100 Phase 4 Shenyankangfu tablets;Losartan potassium 50mg;Shenyankangfu tablets and Losartan potassium 50mg;Shenyankangfu tablets and Losartan potassium 100mg;Losartan potassium 100mg
5 A Multi-center, Open Label, Randomized Study of Effects and Safety Between Adefovir Dipivoxil Plus Polyene Phosphatidylcholine Capsule Versus Adefovir Dipivoxil Alone in Chronic Hepatitis B Patients Unknown status NCT01436539 Phase 4 Adefovir Dipivoxil and polyene phosphatidylcholine;Adefovir Dipivoxil
6 Eplerenone and Aliskiren Research Targeting Hypertensive Patients With Left Ventricular Hypertrophy Unknown status NCT01893788 Phase 4 Aliskiren;Eplerenone
7 The Efficacy and Safety of the Anti Hepatitis B Placenta Transfer Factor Injection in the Treatment of HBeAg Positive Chronic Hepatitis B, Randomized, Double Blind, Placebo Controlled, Multi Center Clinical Trial Unknown status NCT02412319 Phase 4 Anti-HBV placenta transfer factor injection
8 A Phase IV Multicenter Study of the Efficacy and Safety of 48-Week Induction Treatment With TRIZIVIR (Abacavir 300 Mg/Lamivudine 150 Mg/Zidovudine 300 Mg Combination Tablet BID) With Efavirenz (600 Mg QD) Followed by 48-Week Randomized, Open-Label, Maintenance Treatment With TRIZIVIR With or Without Efavirenz in HIV-1 Infected Antiretroviral Therapy Naive Subjects Unknown status NCT00011895 Phase 4 Abacavir sulfate, Lamivudine and Zidovudine;Efavirenz
9 Multi-center, Randomized, Open Label, Comparative, Phase IV Study to Evaluate the Efficacy and Safety of a Combination of Mycophenolate Mofetil and Corticosteroid for 48 Weeks in Advanced IgA Nephropathy Unknown status NCT02981212 Phase 4 Mycophenolate Mofetil;ACE inhibitor;Corticosteroid;ARB
10 The Effect of Ketamine on Production of Inflammatory Markers in Post Operative Patients in Mulago Hospital: A Randomized Clinical Trial Unknown status NCT01339065 Phase 4 Ketamine
11 A Prospective, Randomized, Multicenter, Open-label, Exploratory Study of Utilizing of "Response-Guided-Therapy (RGT)" Strategy on Optimal Nucleoside Analogue (NUC)-Experienced Patients Unknown status NCT02560649 Phase 4 Peginterferon alfa-2a plus Entecavir;Peginterferon alfa-2a plus Lamivudine;Peginterferon alfa-2a plus Adefovir;Peginterferon alfa-2a plus Tenofovir;Entecavir;Lamivudine;Adefovir;Tenofovir disoproxil
12 Efficacies of Entecavir Add on Chronic Hepatitis B Patients With HBV DNA Load ≥1000 Copies/ml After 6 Months Treatment of Peginterferon Alpha 2a Unknown status NCT02368288 Phase 4 entecavir
13 Efficacies of Entecavir Add on HBeAg Negative Chronic Hepatitis B Patients With HBV DNA Load ≥1000 Copies/ml After 3 Months of Peginterferon Alpha 2a Treatment Unknown status NCT02365402 Phase 4 Entecavir
14 Open, Randomized and Multicenter Phase IV Study to Compare the Efficacy and Safety of Two Different Treatments Duration 24 Versus 48 Weeks in Chronic Hepatitis C Genotypes 2 and/or 3 co-Infected HIV-HCV Patients. Unknown status NCT00611819 Phase 4 Peg interferon + Ribavirin;Peg interferon + Ribavirin
15 Prospective, Double-blinded, Randomised, Placebo Controlled Trial of Pre-emptive Analgesia to Prevent Pain Following Sternotomy for Cardiac Surgery. Unknown status NCT01480765 Phase 4 Pregabalin;Ketamine infusion;Placebo capsules;Placebo infusion
16 Sedation of Mechanically Ventilated Critically Ill Patients: Midazolam Versus Dexmedetomidine Unknown status NCT01256866 Phase 4 Dexmedetomidine;Midazolam
17 Prospective Analysis of the Incidence of Ventilator-associated Pneumonia Related to the Humidification System: Heat and Moisture Exchanger Versus Heated Humidification Unknown status NCT01546974 Phase 4
18 Transfer From Methadone to Buprenorphine Maintenance Treatment Using Buprenorphine Patches: A Study on Practicability With Patients Maintained With Daily Dosages Between 60mg and 100mg Methadone. Unknown status NCT00750217 Phase 4 Buprenorphine patch and sublingual tablets
19 Efficacy and Safety of an Initial Regimen Raltegravir (RAL) + Lamivudine/Abacavir Fixed-Dose Combination (3TC/ABC FDC) for 48 Weeks in ART-naïve, HIV/TB Co-Infected Adult Subjects Receiving Rifabutin-containing, 1-line Anti-TB Therapy Unknown status NCT01059422 Phase 4 Raltegravir; Abacavir/Lamivudine
20 A Randomised, Multi-Centre, Open-Label Study in Well-Controlled Treatment-Experienced HIV-Infected Patients to Assess Compliance With a Once-Daily Regimen of Lamivudine, Efavirenz and Didanosine Versus Continuation of Current Anti-Retroviral Regimen Delivered at Least Twice Daily Unknown status NCT00214435 Phase 4 once daily minimum 3-drug regimen of anti-retroviral medications
21 A Randomized Comparison of Two Albumin Administration Schedules for Spontaneous Bacterial Peritonitis Unknown status NCT00761098 Phase 4 Standard Care;Experimental
22 A Multicenter, Open-label, Prospective Study to Evaluate Antiviral Efficacy and Safety of Entecavir Plus Tenofovir Combination in Subjects With Multi-drug Resistant Chronic Hepatitis B Virus Infection Unknown status NCT01594905 Phase 4 Entecavir + Tenofovir (MDR group)
23 A Single Center, Prospective Phase IV, Open-Label, Randomized Trial Comparing the Efficacy , Tolerability, and Safety of Quadritherapy Regimen (Reiferon Retard® + Ribavirin + Nitazoxanide + Alfacalcidol ( Bon-One ®) ) Versus Triple Therapy Regimen (Reiferon Retard® + Ribavirin + Nitazoxanide) Versus the Standard of Care Regimen(Reiferon Retard® + Ribavirin) in the Treatment of Naïve Chronic Hepatitis- C Among the Egyptian Population. Effectiveness Will be Evaluated Based on Sustained Viral Response (SVR) Unknown status NCT01896609 Phase 4 Bon one in Arm 3;Xerovirinc in Arm 2;Ribavirin in Arm 1
24 A Randomized, Controlled, Open-label, Multicenter Clinical Trial to Evaluate the Addition of PegIFN Alfa-2a to CHB Patients Treated With Nucleot(s)Ides Unknown status NCT02644538 Phase 4 PegIFN alfa-2a
25 Post Operative Pain Control Among Intrathecal 0.1 mg Morphine, Femoral Nerve Block, or Periarticular Infiltration of 20 mL of 0.25% Bupivacaine in Patients Post Intramedullary Hip Screw Unknown status NCT01219088 Phase 4 Bupivacaine, morphine
26 Impact of Starting a Dolutegravir-based Regimen on HIV-1 Proviral DNA Reservoir Of Treatment Naïve and Experienced Patients Unknown status NCT02370979 Phase 4
27 A Phase IV, Open Label, Multi-Center, Study of Maintenance Intravitreous Injections of Macugen (Pegaptanib Sodium) Given Every 6 Weeks for 48 Weeks in Subjects With Subfoveal Neovascular Age-Related Macular Degeneration (AMD) Initially Treated With a Modality Resulting in Maculopathy Improvement Unknown status NCT00354445 Phase 4 pegaptanib sodium (Macugen)
28 An Open, Single-Arm, Multi-Center, Phase IV Pilot Study of Treatment of Antiretroviral Naive HIV-1 Infected Patients With Tenofovir Disoproxil Fumarate in Combination With Emtricitabine and Zidovudine Unknown status NCT00199121 Phase 4 Zidovudine (drug)
29 Efficacy and Safety of a Hansenula-derived Pegylated Interferon α2a (Reiferon Retard®) in Treatment of Patients With Chronic Hepatitis C Virus Infection: A National Multi-center Phase IV Open Label Non-Randomized Trial Unknown status NCT01649245 Phase 4 Reiferon retard
30 Chlorhexidine Gluconate for Prevention of Ventilator Associated Pneumonia in a Pediatric Intensive Care Unit. Unknown status NCT01883596 Phase 4 0.12% chlorhexidine solution;Placebo
31 Programmatic Implementation of ACTs in Malawi: Safety and Effectiveness of Combination Therapies With Repeated Treatments for Uncomplicated P. Falciparum Malaria Over a Three-year Period Unknown status NCT01038063 Phase 4 Artemether-lumefantrine combination
32 Postoperative Analgesia After Thoracotomy Without Thoracic Epidural Analgesia: Continuous Wound Catheter Analgesia Associated With Intravenous Morphine Patient-Controlled-Analgesia (PCA) Unknown status NCT01698203 Phase 4 ropivacaine 0.75% - device : wound catheter Silver™ 19 cm and Easypump™ 400 mL (BBraun);Placebo;ropivacaine 0.2% - device : wound catheter Silver™ 19 cm and Easypump™ 400 mL (BBraun)
33 A Clinical Trial of the Effect of Midazolam on the Cerebral Metabolism and Inflammatory Response in Patients With Moderate and Severe Traumatic Brain Injury Unknown status NCT02071407 Phase 4 Midazolam;Placebo
34 Neutrophil gElatinase-associated Lipocalin alloWs Intensive treatMent Of cOntrast Induced Nephropathy in Patients With Urgent/Emergency Percutaneous Coronary Intervention Unknown status NCT01491243 Phase 4 Intensive treatment with sodium bicarbonate;Standard treatment with saline infusion
35 Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy: a Multicentre, Double-blind, Double-dummy, Randomized Controlled Trial Unknown status NCT02231125 Phase 4 Losartan;Abelmoschus manihot
36 A Multi Center, Phase IIIb Study to Evaluate the Efficacy of Response Guided Therapy Using Quantitative HBsAg Measurement in Patient With HBeAg Positive Chronic Hepatitis B: Unknown status NCT01456312 Phase 4 Peginterferon alfa-2a;Entecavir
37 Naproxen for Acute Pain After Surgery: A Randomized, Placebo-Controlled Trial Unknown status NCT00615875 Phase 4 naproxen;placebo
38 Impact of Pretreatment With Omega 3 Enriched Lipid Emulsion on Early Neurological Complications After Living Donor Liver Transplantation. A Randomized Controlled Trial> Unknown status NCT02544919 Phase 4 SMOF lipid (SMOFLIPID) pre treatment
39 Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease Unknown status NCT00941642 Phase 4 Lovaza;placebo control
40 Analysis of Proximal Renal Tubular Function of "Real World" Chronic Hepatitis B (CHB) Patients Who Are Suppressed on TDF and Switched to TAF Unknown status NCT02957994 Phase 4 Tenofovir alafenamide fumarate
41 Multicenter Prospective Trial to Investigate Accuracy of Ultrasound to Predict Relapse After Discontinuation of Infliximab and Efficacy/Safety of Readministration of Infliximab in Patients With Rheumatoid Arthritis in Low Disease Activity Unknown status NCT02770794 Phase 4 Infliximab
42 Effect of Vitamin D Supplementation on Bone Turnover Markers During Tenofovir-Emtricitibine Pre-Exposure Prophylaxis in Men Who Have Sex With Men; A Sub-study of CCTG 595 Unknown status NCT02367599 Phase 4 Vitamin D Supplement
43 Adductor Canal Block Versus Femoral Nerve Block for Analgesia After Anterior Cruciate Ligament Reconstruction Arthroscopically Unknown status NCT02355093 Phase 4 ropivacaine
44 Emtricitabine for Prevention of Vertical Transmission of HBV in Chinese Pregnant HBsAg Positive Patients Unknown status NCT02327715 Phase 4 Emtricitabine
45 Emtricitabine for Naive Child Chinese Chronic Hepatitis B Patients Unknown status NCT02327676 Phase 4 Emtricitabine
46 Albumin Infusion Effects in Mortality in Patients With Cirrhosis and Hepatic Encephalopathy Unknown status NCT02401490 Phase 4 Human albumin;Placebo
47 Effects of 2 Initial Standard Antiretroviral Combinations Therapies on Lipid Metabolism in ARV-naive HIV-infected Subjects Unknown status NCT00759070 Phase 4 Tenofovir + emtricitabine + efavirenz;Tenofovir + emtricitabine + lopinavir/ritonavir
48 Open Label Phase 4, 48 Week Pilot Study of the Antiviral Efficacy and Tolerability of the Combination of Isentress™ and ReyatazTM When Substituted for Current Antiviral Regimen in Patients With Viral Suppression But Who Are Experiencing Adverse Events Related to Their Current Antiviral Regimen. Unknown status NCT00751153 Phase 4 Raltegravir and Atazanavir
49 Mycophenolate Mofetil in Antiretroviral Naïve Patients 2 (MAN2 Study) Unknown status NCT00120419 Phase 4 mycophenol mofetil (MMF, Cellcept®) 500 mg BID
50 Antibiotic Prophylaxis in Prosthetic Breast Reconstructions Unknown status NCT02012517 Phase 4 Prolonged antibiotic treatment;Short antibiotic course (standard of care)

Search NIH Clinical Center for 48,xyyy

Genetic Tests for 48,xyyy

Anatomical Context for 48,xyyy

MalaCards organs/tissues related to 48,xyyy:

40
Testes, Liver, Lung, Brain, Kidney, Heart, Breast

Publications for 48,xyyy

Articles related to 48,xyyy:

(show top 50) (show all 30000)
# Title Authors PMID Year
1
Isolation of virulent phages infecting dominant mesophilic aerobic bacteria in cucumber pickle fermentation. 61
31703878 2020
2
Efficacy of Systemic Steroid Use Given One Day After Total Knee Arthroplasty for Pain and Nausea: A Randomized Controlled Study. 61
31563397 2020
3
Changes in Fatigue Are the Same for Trained Men and Women after Resistance Exercise. 61
31343516 2020
4
A short period of dark-adaptation is sufficient to generate light-induced photoreceptor degeneration in pigmented zebrafish. 61
31789762 2020
5
Subtyping of Swine Influenza Using a High-Throughput Real-Time PCR Platform and a Single Microfluidics Device. 61
31667759 2020
6
Effect of nitrite exposure on oxidative stress, DNA damage and apoptosis in mud crab (Scylla paramamosain). 61
31494325 2020
7
Factors Associated with Symptomology of Celiac Artery Compression and Outcomes following Median Arcuate Ligament Release. 61
31449931 2020
8
Prognostic Value of Tissue Oxygen Monitoring and Regional Cerebral Oxygen Saturation Monitoring and Their Correlation in Neurological Patients with Sepsis: A Preliminary, Prospective, Observational Study. 61
30475291 2020
9
Deflazacort vs prednisone treatment for Duchenne muscular dystrophy: A meta-analysis of disease progression rates in recent multicenter clinical trials. 61
31599456 2020
10
Impact of ART on dynamics of growth factors and cytokines in primary HIV infection. 61
31542514 2020
11
The impact of social relationships on children's distributive justice. 61
31763865 2020
12
Evaluation of MASTDISCS combi Carba plus for the identification of metallo-β-lactamases, KPC and OXA-48 carbapenemase genes in Enterobacteriaceae clinical isolates. 61
31642085 2020
13
Structure-activity relationship studies and in vitro and in vivo anticancer activity of novel 3-aroyl-1,4-diarylpyrroles against solid tumors and hematological malignancies. 61
31727471 2020
14
Development of a mass spectrometric screening assay for hepatitis B virus entry inhibitors. 61
31722821 2020
15
Pro-vitamin A carotenoid content of 48 plantain (Musa AAB genome) cultivars sourced from eastern Democratic Republic of Congo. 61
31591722 2020
16
Vitamin D3 supplementation and neurofilament light chain in multiple sclerosis. 61
31657006 2020
17
Validating the Utility of High Frequency Ocular Vestibular Evoked Myogenic Potential Testing in the Diagnosis of Superior Semicircular Canal Dehiscence. 61
31725592 2019
18
Cat bite: an injury not to underestimate. 61
31287352 2019
19
[Application of ultrasonography scoring system in the assessment of IgG4-related sialadenitis]. 61
31848499 2019
20
Effect on Bleeding Prevention of an Intravenous Proton Pump Inhibitor During the Fasting Period After Endoscopic Submucosal Dissection: a Prospective, Randomized, Double-Blind, Placebo-Controlled Trial. 61
31845139 2019
21
Diuretic Strategies for Loop Diuretic Resistance in Acute Heart Failure: The 3T Trial. 61
31838029 2019
22
Altered triglyceride and phospholipid metabolism predates the diagnosis of gestational diabetes in obese pregnancy. 61
31599289 2019
23
Randomized Comparison Study of Novel Recombinant Human Antithrombin Gamma and Plasma-Derived Antithrombin in Healthy Volunteers. 61
31493216 2019
24
Pharmacokinetics, Pharmacodynamics, and Safety of a Single Escalating Dose and Repeated Doses of Rasagiline Transdermal Patch in Healthy Chinese Subjects. 61
31823527 2019
25
Acidified water impairs the lateral line system of zebrafish embryos. 61
31711007 2019
26
Long-term retention of acoustic telemetry transmitters in temperate predators revealed by predation tags implanted in wild prey fish. 61
31605542 2019
27
Impact of menopausal hormone formulations on pituitary-ovarian regulatory feedback. 61
31663769 2019
28
Effect of 5-aminolevulinic acid photodynamic therapy on the expression of apoptosis inhibitors Bcl-2 and Survivin in keratinocytes of condyloma acuminatum. 61
31349100 2019
29
Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I. 61
31430369 2019
30
Efficacy and safety of interferon alpha-2b versus pegylated interferon alpha-2a monotherapy in children with chronic hepatitis B: a real-life cohort study from Shanghai, China. 61
31487005 2019
31
Time to Surgery and Patient Mortality in Geriatric Acetabular Fractures. 61
31821276 2019
32
Brain Injury Biomarker Behavior in Spontaneous Intracerebral Hemorrhage. 61
31449996 2019
33
Association of Ang-2, vWF, and EVLWI with risk of mortality in sepsis patients with concomitant ARDS: A retrospective study. 61
31822372 2019
34
Evaluation of an anaerobic baffled reactor for pretreating black water: Potential application in rural China. 61
31561140 2019
35
Anti-hydroxy-3-methylglutaryl-coenzyme A reductase (anti-HMGCR) antibody in necrotizing myopathy: treatment outcomes, cancer risk, and role of autoantibody level. 61
31801390 2019
36
Polymorphisms in TNF Receptor Superfamily 1B (TNFRSF1B:rs3397) are Linked to Mycobacterium avium paratuberculosis Infection and Osteoporosis in Rheumatoid Arthritis. 61
31817071 2019
37
Expression of the Immune Checkpoints LAG-3 and PD-L1 in High-grade Serous Ovarian Carcinoma: Relationship to Tumor-associated Lymphocytes and Germline BRCA Status. 61
31851060 2019
38
The Characteristics of Glucose Homeostasis in Grass Carp and Chinese Longsnout Catfish after Oral Starch Administration: A Comparative Study between Herbivorous and Carnivorous Species of Fish. 61
31813383 2019
39
Patients with schizophrenia have impaired muscle force-generating capacity and functional performance. 61
31359490 2019
40
[Effects of Recombinant Human Thrombopoietin on Funtion of T and B Lymphocyte in Prieary ITP Patients]. 61
31839067 2019
41
Microbiological changes observed over 48 weeks of treatment with inhaled liposomal ciprofloxacin in individuals with non-cystic fibrosis bronchiectasis and chronic Pseudomonas aeruginosa lung infection. 61
31035017 2019
42
Clinical Guideline Highlights for the Hospitalist: Initial Management of Acute Pancreatitis in the Hospitalized Adult. 61
31634105 2019
43
The benefit of delayed reassessment post high-volume CSF removal in the diagnosis of shunt-responsive idiopathic normal-pressure hydrocephalus. 61
31843431 2019
44
Ruptured anomalous hyperplastic anterior choroidal artery aneurysm: a case report. 61
31835919 2019
45
Two-stage combined treatment of leiomyosarcoma of iliac vein using robotic surgery. 61
31799486 2019
46
Rheumatologists' awareness of hepatitis B reactivation before immunosuppressive therapy. 61
31520109 2019
47
Effectiveness and safety of combined neurokinin-1 antagonist aprepitant treatment for multiple-day anthracycline-induced nausea and vomiting. 61
30709557 2019
48
Cost per response for guselkumab versus adalimumab in the United States using data from a head-to-head trial in moderate-to-severe plaque psoriasis. 61
31199173 2019
49
Comparative evaluation of hesperetin loaded nanoparticles for anticancer activity against C6 glioma cancer cells. 61
30688095 2019
50
Accelerated cell turnover 48 h after intestinal ischemia is NOTCH independent. 61
31576469 2019

Variations for 48,xyyy

Expression for 48,xyyy

Search GEO for disease gene expression data for 48,xyyy.

Pathways for 48,xyyy

GO Terms for 48,xyyy

Sources for 48,xyyy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....